CoChat

Endocannabinoid System Components as Potential Biomarkers in Psychiatry

Open access
Navarrete, Francisco, García-Gutiérrez, María Salud, Jurado-Barba, Rosa, Rubio, Gabriel, Gasparyan, Ani, Austrich-Olivares, Amaya, Manzanares, Jorge · 2020 · Frontiers in Psychiatry
Cited by 133

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

The high heterogeneity of psychiatric disorders, leads to a lack of diagnostic precision. Therefore, the search of biomarkers is a fundamental aspect in psychiatry to reach a more personalized medicine. The endocannabinoid system (ECS) has gained increasing interest due to its involvement in many different functional processes in the brain, including the regulation of emotions, motivation and cognition. This article reviews the role of the main components of the ECS as biomarkers in certain psychiatric disorders. Studies carried out in rodents evaluating the effects of pharmacological and genetic manipulation of cannabinoid receptors or endocannabinoids (eCBs) degrading enzymes. Likewise, the ECS-related alterations occurring at the molecular level in animal models reproducing some behavioral and/or neuropathological aspects of psychiatric disorders were reviewed. Clinical studies evaluating gene or protein alterations in post-mortem brain tissue or in vivo blood, plasma and cerebrospinal fluid (CSF) samples were analyzed. Furthermore, the results from neuroimaging studies using positron emission tomography (PET) or functional magnetic resonance (fMRI) were included. This review shows the close involvement of cannabinoid receptor 1 (CB1r) in stress regulation and the development of mood disorders (anxiety, depression, bipolar disorder (BD)), in post-traumatic stress disorder (PTSD), as well as in the etiopathogenesis of schizophrenia, attention deficit hyperactivity disorder (ADHD) or eating disorders (i.e. anorexia and bulimia nervosa). On the other hand, recent results regarding the potential therapeutic action of the endocannabinoid tone manipulation by inhibition of eCBs degrading enzymes, as well as by the modulation of cannabinoid receptor 2 (CB2r) activity on anxiolytic, antidepressive or antipsychotic associated effects were included. Further clinical research studies are needed, however, current evidence suggests that the components of the ECS may become promising biomarkers in psychiatry to improve, at least in part, the diagnosis and pharmacological treatment of psychiatric disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2020.00315

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 133

Metadata

Authors
Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J.
Venue
Frontiers in Psychiatry
Published
2020-04-27
Volume
11
Pages
315-315
ISSN
1664-0640 (ISSN-L)
OpenAlex
W3019308918
Cited by
133
References
69
FWCI
8.77
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endocannabinoid System Components as Potential Biomarkers in Psychiatry. https://app.cochat.ai/papers/10.3389/fpsyt.2020.00315
The paper
Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020). Endocannabinoid System Components as Potential Biomarkers in Psychiatry. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2020.00315

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.